29 studies found for:    Open Studies | "intraocular melanoma"
Show Display Options
Rank Status Study
1 Recruiting Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Extraocular Extension Melanoma;   Iris Melanoma;   Liver Metastases;   Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma;   Stage IV Intraocular Melanoma
Interventions: Biological: ipilimumab;   Radiation: yttrium Y 90 glass microspheres;   Other: laboratory biomarker analysis
2 Not yet recruiting Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Iris Melanoma;   Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIC Intraocular Melanoma;   Stage IV Intraocular Melanoma
Interventions: Drug: cabozantinib-s-malate;   Drug: temozolomide;   Drug: dacarbazine;   Other: laboratory biomarker analysis
3 Recruiting Vorinostat in Treating Patients With Metastatic Melanoma of the Eye
Conditions: Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma
Interventions: Drug: vorinostat;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Genetic: western blotting;   Other: immunohistochemistry staining method;   Other: diagnostic laboratory biomarker analysis
4 Recruiting Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Iris Melanoma;   Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma
Interventions: Drug: selumetinib;   Drug: temozolomide;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
5 Recruiting Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye
Condition: Intraocular Melanoma
Interventions: Biological: bevacizumab;   Drug: temozolomide;   Genetic: polymorphism analysis;   Other: pharmacogenomic studies
6 Recruiting Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma
Condition: Uveal Melanoma
Intervention:
7 Not yet recruiting Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma
Conditions: Macular Edema;   Cystoid Macular Edema;   Uveal Melanoma;   Radiation Maculopathy;   Radiation Retinopathy
Intervention: Drug: Ozurdex (Dexamethasone intravitreal implant )
8 Recruiting Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients
Condition: Uveal Melanoma
Intervention: Drug: AEB071
9 Recruiting Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients
Condition: Uveal Melanoma
Intervention: Biological: autologous dendritic cells electroporated with mRNA
10 Recruiting Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma
Condition: Uveal Melanoma
Intervention: Radiation: Hypofractionated linear accelerator radiotherapy
11 Recruiting A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma
Condition: Uveal Melanoma
Interventions: Drug: Placebo;   Drug: Sorafenib
12 Recruiting RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
Condition: Uveal Melanoma
Intervention: Drug: RAD001 (Everolimus) and Pasireotide (SOM230) LAR
13 Not yet recruiting A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
Condition: Uveal Melanoma
Interventions: Drug: AEB071;   Drug: MEK162
14 Unknown  Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma
Condition: Intraocular Melanoma
Interventions: Drug: cisplatin;   Drug: sunitinib malate;   Drug: tamoxifen citrate;   Procedure: adjuvant therapy
15 Recruiting Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma
Condition: Metastatic Malignant Uveal Melanoma
Intervention: Drug: Marqibo® (vincristine sulfate liposomes injection)
16 Recruiting Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Conditions: Brain and Central Nervous System Tumors;   Intraocular Melanoma;   Lung Cancer;   Melanoma (Skin);   Metastatic Cancer;   Neuroblastoma;   Ovarian Cancer;   Retinoblastoma;   Sarcoma;   Small Intestine Cancer
Interventions: Genetic: DNA analysis;   Other: immunologic technique;   Other: pharmacological study;   Radiation: iodine I 131 monoclonal antibody 3F8;   Radiation: 131I-3F8
17 Recruiting A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma
Condition: Metastatic Uveal Melanoma
Interventions: Drug: Dacarbazine;   Drug: Sunitinib
18 Recruiting Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy
Condition: Uveal Melanoma
Interventions: Dietary Supplement: CITICOLINE;   Dietary Supplement: PLACEBO
19 Recruiting SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver
Condition: Stage IV Uveal Melanoma
Intervention: Device: Sir-Spheres®
20 Unknown  Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom
Conditions: Bladder Cancer;   Brain and Central Nervous System Tumors;   Esophageal Cancer;   Intraocular Melanoma;   Kidney Cancer;   Lymphoma;   Melanoma (Skin);   Pancreatic Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions: Genetic: DNA analysis;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis;   Other: questionnaire administration

Previous Page Studies Shown (1-20) Next Page (21-29) Show next page of results
Indicates status has not been verified in more than two years